Tocilizumab in a Case of Refractory Idiopathic Orbital Inflammation: 6-Year Follow-Up Outcomes
Idiopathic orbital inflammation (IOI) is a noninfectious inflammatory disease whose etiology remains unknown. Treatment is focused on reducing inflammation, which becomes challenging in nonresponding cases. We report the case of a 59-year-old woman with refractory IOI that showed a positive response...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2020-07-01
|
Series: | Case Reports in Ophthalmology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/508237 |
id |
doaj-bfb9504cd9b9459f8cd0c05e83949048 |
---|---|
record_format |
Article |
spelling |
doaj-bfb9504cd9b9459f8cd0c05e839490482020-11-25T01:56:08ZengKarger PublishersCase Reports in Ophthalmology1663-26992020-07-0111229930510.1159/000508237508237Tocilizumab in a Case of Refractory Idiopathic Orbital Inflammation: 6-Year Follow-Up OutcomesJune Artaechevarria ArtiedaIgnacio Tapias EliasIdiopathic orbital inflammation (IOI) is a noninfectious inflammatory disease whose etiology remains unknown. Treatment is focused on reducing inflammation, which becomes challenging in nonresponding cases. We report the case of a 59-year-old woman with refractory IOI that showed a positive response to tocilizumab therapy. The patient was diagnosed with a unilateral sclerosing IOI for 9 years and showed a negative control with previous oral steroids, peribulbar steroid injections, radiotherapy, immunosuppressors, and intravenous rituximab. After the initiation of 8 mg/kg intravenous tocilizumab, a complete reduction of the pain and the orbital inflammation signs was observed and her condition remained stable for the following 6 years under a monthly dose of 4 mg/kg. In recalcitrant IOI cases, tocilizumab could be considered a possible treatment to reduce inflammatory signs and symptoms with positive long-term outcomes as in our case.https://www.karger.com/Article/FullText/508237idiopathic orbital inflammationtocilizumaborbitinflammationeye |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
June Artaechevarria Artieda Ignacio Tapias Elias |
spellingShingle |
June Artaechevarria Artieda Ignacio Tapias Elias Tocilizumab in a Case of Refractory Idiopathic Orbital Inflammation: 6-Year Follow-Up Outcomes Case Reports in Ophthalmology idiopathic orbital inflammation tocilizumab orbit inflammation eye |
author_facet |
June Artaechevarria Artieda Ignacio Tapias Elias |
author_sort |
June Artaechevarria Artieda |
title |
Tocilizumab in a Case of Refractory Idiopathic Orbital Inflammation: 6-Year Follow-Up Outcomes |
title_short |
Tocilizumab in a Case of Refractory Idiopathic Orbital Inflammation: 6-Year Follow-Up Outcomes |
title_full |
Tocilizumab in a Case of Refractory Idiopathic Orbital Inflammation: 6-Year Follow-Up Outcomes |
title_fullStr |
Tocilizumab in a Case of Refractory Idiopathic Orbital Inflammation: 6-Year Follow-Up Outcomes |
title_full_unstemmed |
Tocilizumab in a Case of Refractory Idiopathic Orbital Inflammation: 6-Year Follow-Up Outcomes |
title_sort |
tocilizumab in a case of refractory idiopathic orbital inflammation: 6-year follow-up outcomes |
publisher |
Karger Publishers |
series |
Case Reports in Ophthalmology |
issn |
1663-2699 |
publishDate |
2020-07-01 |
description |
Idiopathic orbital inflammation (IOI) is a noninfectious inflammatory disease whose etiology remains unknown. Treatment is focused on reducing inflammation, which becomes challenging in nonresponding cases. We report the case of a 59-year-old woman with refractory IOI that showed a positive response to tocilizumab therapy. The patient was diagnosed with a unilateral sclerosing IOI for 9 years and showed a negative control with previous oral steroids, peribulbar steroid injections, radiotherapy, immunosuppressors, and intravenous rituximab. After the initiation of 8 mg/kg intravenous tocilizumab, a complete reduction of the pain and the orbital inflammation signs was observed and her condition remained stable for the following 6 years under a monthly dose of 4 mg/kg. In recalcitrant IOI cases, tocilizumab could be considered a possible treatment to reduce inflammatory signs and symptoms with positive long-term outcomes as in our case. |
topic |
idiopathic orbital inflammation tocilizumab orbit inflammation eye |
url |
https://www.karger.com/Article/FullText/508237 |
work_keys_str_mv |
AT juneartaechevarriaartieda tocilizumabinacaseofrefractoryidiopathicorbitalinflammation6yearfollowupoutcomes AT ignaciotapiaselias tocilizumabinacaseofrefractoryidiopathicorbitalinflammation6yearfollowupoutcomes |
_version_ |
1724981238469492736 |